2025 Newsletter

Contents…

2024 - 2025 IVAMSS Officers
President Samantha C. Faber
Past President Kristie M. Sullivan
Vice President Shaun McCullough
Vice President-Elect Emily Reinke
Secretary Maureen Bunger
Treasurer Deniz Emul
Councilors Melissa M. Martin Anthony Bahinski
Postdoctoral Representative Erin A. Huber
Graduate Student Representative Jessica R. Rodriguez

Letter from the President

Samantha C. Faber
Principal Scientist, Amgen
IVAMSS President

Dear IVAMSS Members,

Welcome to the Spring 2025 edition of our newsletter! We're thrilled to reconnect with you and share the exciting strides being made in the world of *in vitro* and alternative methods in toxicology. These innovative approaches are not just advancing our science—they're transforming the way we think about safety, ethics, and the future of toxicology.

In vitro and alternative methods align closely with the core principles of the 3Rs—Reduction, Refinement, and Replacement. By reducing the number of animals used, refining testing techniques to support animal welfare, and ultimately replacing outdated animal models with more ethical, accurate, and human-relevant alternatives, we are driving safer product development, more reliable regulatory decisions, and paving the way for a more sustainable future in toxicology research.

What's even more exciting is the growing global adoption of New Approach Methods (NAMs). This progress is expanding beyond traditional leaders like North America, the European Union, and Japan. Our Past-President, Kristie Sullivan, will provide insights into these global advancements and the collaborative efforts between regulatory bodies, research institutions, and industry partners around the world.

In the coming months, we will be reaching out to gather your input as we work to define the scope of our specialty section. What exactly constitutes an *in vitro* or alternative method within the IVAMSS community? It's a nuanced issue, but as we receive increasing questions about session proposal endorsements and annual award eligibility, it's time to have this important conversation. Your thoughts and feedback are crucial to shaping our guidelines, and we're committed to ensuring that any decisions—whether related to awards, session proposals, or bylaws—are made with thorough member engagement. We hope to see you at the Annual Meeting reception, where you can share your views and help guide our direction.

Speaking of the Annual Meeting, mark your calendars for the IVAMSS reception at the 2025 SOT Annual Meeting in Orlando, FL, on Wednesday, March 19th, from 6:00–7:30 PM in the Hyatt Regency Ballroom U. We hope you'll join us for an evening of conversation, connection, and celebration, and be sure to read on for a sneak peek at the sessions endorsed by IVAMSS related to *in vitro* and alternative methods at the Annual Meeting.

In this edition, we'll also spotlight recent IVAMSS-focused manuscripts, celebrate the achievements of our 2024-2025 IVAMSS awardees, and explore the ongoing global efforts to overcome challenges in implementing *in vitro* and alternative methodologies within regulatory frameworks. Together, we're shaping a future for toxicology that is more ethical, efficient, and sustainable.

Thank you for being part of this exciting journey!

Warmest regards,
Samantha Faber, PhD, DABT
IVAMSS President, 2024-2025

In Vitro and Alternative Methods
IVAM
Specialty Section
of the Society of Toxicology

IVAMSS Announcements

Membership Update:

The IVAMSS was **founded in 1994** and grew steadily until 2016 when membership **peaked at 524**. As of January 2025, IVAMSS had **338 members**. Our members come from industry, academia, government, contract research organizations, research institutes, and consulting. The majority of IVAMSS members are full members of SOT. Our membership includes representation internationally and retired toxicologists. The charts provided summarize IVAMSS membership.







Annual Updates

Treasurer's Report:

Deniz Emul
Senior Biocompatibility Engineer, ResMed
IVAMSS Treasurer

In February 2024, IVAMSS had net assets of $21,741. As of October 2024, $9,189 was received in contributions, membership dues, and interest. Expenses amounting to $11,301 were incurred for the reception at SOT 2024, awards, plaques, activities and resources. Therefore, IVAMSS has net assets of $19,979.

Welcome New IVAMSS Officers!

Vice President-Elect: ***Shannon M. Bell***

Councilor: ***Amy Mihalchik***

Postdoctoral Representative: ***Thant M. Soe***

2024 - 2025 IVAMSS Highlight:

We reviewed **28** Session proposals submitted in May 2024 for SOT's 2025 Annual Meeting. Of the selected proposals IVAMSS is the primary endorser for **8** sessions.

In Vitro and Alternative Methods Specialty Section of the Society of Toxicology
IVAM

Award Winners

In March 2024, we had another in-person SOT Annual Meeting, during which the IVAMSS award winners were announced. The winner of the Graduate Student Award was **Lucie Ford** from Texas A&M University *(top left)* and the winner of both the Postdoctoral and MB Research Awards was **Dr. Erin Huber** from RTI International (*top middle)*. The IVAMSS Best Poster Award winner was **Victoria Colvin** from Oregon State University *(top right)* and the Elsevier Best Poster Award winner was **Jui-Feng Tsai** from National Taiwan University (*bottom right*). Finally, the Best Paper Award went to **Dr. Rhiannon David** from AstraZeneca (*bottom left)*. Congratulations again to all of our 2024 winners!

Lucie Ford: Graduate Student Award Winner

Dr. Erin Huber: Postdoctoral and MB Research Award Winner

Victoria Colvin: Best Poster Award Winner

Dr. Rhiannon David: Best Paper Award Winner

Jui-Feng Tsai: Elsevier Best Poster Award Winner

In Vitro and Alternative Methods
IVAM
Specialty Section
of the Society of Toxicology

Featured Topic: New Approach Methods – A Worldwide Phenomenon

Kristie Sullivan, MPH
Vice President, Education and Outreach
Institute for In Vitro Sciences
IVAMSS Past President

Historically, scientists from North America, the European Union, and Japan have worked to develop and validate *in vitro* and *in silico* models and approaches to meet toxicological needs for research, product development, and regulatory decision-making, while responding to ethical standards to reduce and replace the use of animals. In the past decade or so, however, efforts to adopt these methods for use in other countries have quickly arisen and expanded.

China is perhaps the most dramatic example. Despite not being part of the Organization for Economic Cooperation and Development (OECD), Chinese regulators and scientists are striving to adopt OECD *in vitro* methods and develop the infrastructure and capabilities to use a variety of New Approach Methods (NAMs) across a large and diverse regulatory landscape, and have released several guidelines over the years to indicate acceptance of *in vitro* methods, in particular for cosmetic safety assessment. In 2024, China released guidance allowing the use of read-across and a Defined Approach for Skin Sensitization. Additionally, MatTek has partnered with local laboratory Cellex to produce *in vitro* three-dimensional human tissues for a variety of methods, addressing an issue that plagues many regions: availability and cost of human tissue models for testing. This October, Beijing will host the International Congress on Toxicology 2025, which promises to highlight NAMs development within the country and promote collaboration with toxicologists from around the world.

Chinese regulators joined the exciting events in December 2024 to establish the Asian Federation of Societies for Alternatives to Animal Experiments, bringing together scientific societies focused on alternative methods in toxicology from Japan, India, Sri Lanka, Korea, and China, during the 4th Asian Congress for Alternatives to Animal Experiments on Non-Animal Approaches: Concept, Validation, and Regulatory Acceptance in New Delhi, India. This event highlighted a variety of NAMs across pharmaceutical, chemical, and pesticide sectors, and included the engagement of CROs, universities, and new technology start-ups across India working in this field. A highlight session featured perspectives from CropLife India, PETA India, and the Ministry of Agriculture discussing the willingness of India's pesticide regulators to accept validated *in vitro* methods and efforts to conduct training for domestic companies and laboratories in these methods.

In South America, the development of chemical regulatory frameworks and NAMs laboratory capacity and training networks are proceeding concurrently. This was highlighted by sessions at the April 2024 Congress of Toxicology in Developing Countries in Chile detailing challenges with assessing pesticide exposure in a variety of populations, addressing acute poisoning issues, using *in silico* models to address environmental toxicology challenges, and the impact of sometimes very low life sciences funding on national and academic laboratories in countries including Brazil, Argentina, and Chile. It is clear that the acceptance of NAMs by regulators within a country is dependent on domestic laboratory and company capabilities, not only connection to OECD practices and guidelines. This summer, discussions will continue at the 13th World Congress on Alternatives and Animal Use in the Life Sciences, to be held in Rio in September 2025.

In terms of systematic use of NAMs, a theme across the global south is that obtaining not only three-dimensional tissue models, but other materials and reagents for conducting *in vitro* testing, is often difficult, expensive, or untimely. Developers of internationally-harmonized guidance and guidelines should consider the unique challenges of countries building their national capabilities and provide for ways to conduct testing within countries where tissue models and other supplies may be harder or more expensive to obtain, for example by encouraging the development of open-source models and performance standards to demonstrate good performance of methods without purchasing specific models. Additionally, scientific societies, trade organizations, validation bodies, and research organizations and institutes all have roles to play in facilitating the growth of NAMs infrastructure and capabilities to promote acceptance around the world.

In Vitro and Alternative Methods
IVAM
Specialty Section
of the Society of Toxicology

Featured Topic: European Commission Roadmap Towards Phasing Out Animal Testing for Chemical Safety Assessment

Gavin Maxwell, PhD
Head of Regulatory Science Strategy & Advocacy - Unilever & EPAA Industry Co-Chair

The European Commission Roadmap towards phasing out animal testing for chemical safety assessment was launched on 25th July 2023 as part of their response to the successful "Save Cruelty Free Cosmetics – Commit to a Europe without Animal Testing' European Citizens" Initiative that received over 1.2 million signatures. The Commission Roadmap aims to outline milestones and specific actions that would be pre-requisites for a transition towards animal-free chemical legislation and ultimately leading to the phase out of animal testing for chemical safety assessment within Europe.

To inform the development of the roadmap the Commission have run a series of stakeholder consultations and workshops (11th December 2023 & 25th October 2024) as well as partnering directly with stakeholder groups (e.g. European Partnership for Alternative Approaches for Animal Testing (EPAA), Partnership for Assessment of Risks from Chemicals (PARC), ASPIS project cluster, European Member State Authorities, Animal Protection NGOs and Industry Trade Associations). Most recently the Commission roadmap leads worked with the EPAA to organize a 3-day Animal-Free Chemical Safety Assessment conference (4th-6th March 2025) where more than 250 invited experts (100 in person, 150 online) worked in themed breakout groups to develop animal-free strategies with short, medium and long-term actions for addressing all aspects of human health and environmental chemical safety assessment (workshop report & publication in development).

The draft Commission roadmap proposal will be shared via a final stakeholder workshop hosted by ECHA on 16th-17th June 2025 (register by 15th May 2025 for in-person participation, virtual participation also possible) ahead of final publication in Q1 2026.

In Vitro and Alternative Methods Specialty Section of the Society of Toxicology

IVAM

Member Spotlight

Congratulations to IVAMSS Members Receiving 2025 SOT Awards

Enhancement of Animal Welfare Award

Nicole Churchill Kleinstreuer, PhD

NIEHS/NICEATM, Morrisville, NC

Colgate-Palmolive Award for Student Research Training in Alternative Methods

Kyle R. Siegel, BS

Wayne State University, Detroit, MI

Trainee Corner

A Message to our fellow IVAMSS Graduate Student and Postdoctoral Members:

First and foremost, welcome to our new and returning IVAMSS graduate and postdoctoral members! We hope you had a happy, healthy, and productive 2024 - 2025. Should you have any suggestions as to what we can incorporate here at IVAMSS to help connect you to the world of *in vitro* and alternative methods, please let us know!

We are excited to share that we are co-hosting a mentoring event with the Medical Device and Combination Product Specialty Section (MDCPSS) this year at SOT. The event will be held on **Monday, March 17th** from **5-6pm** in **Celebration Room 3** of the **Hyatt Regency**. If interested, **sign up here!** We plan to host more of these events in subsequent years, sometimes in collaboration with other specialty sections, so keep an eye out!

We hope that all IVAMSS graduate student and postdoctoral members are able to attend SOT this year, as well as connect with us either at the **IVAMSS Reception** on **Wednesday, March 19th** from **6-7:30pm** in **Regency Ballroom U** of the **Hyatt Regency**, or by stopping by our IVAMSS poster in the ToxExpo Hall.

Other SOT activities that might be of interest to the graduate students and postdocs include luncheons, career-building workshops, posters, and symposia; many of which will be either uploaded or recorded and can be viewed through the SOT online planner. Relevant sessions are listed below in the "SOT 2025 Annual Meeting" section of this newsletter. Remember to keep an eye out for events through the weekly SOT announcements or on our LinkedIn - we'd love to connect!

Safe travels to SOT! We can't wait to see you in sunny Orlando, Florida!

We are wishing you all the best in 2025-2026!!!

JOIN & GET INVOLVED! Trainees are essential to growth and maintenance of IVAMSS! The specialty section is committed to creating opportunities for success in all our research careers. As a member, trainees will have access to all these opportunities. Also, most trainees do not realize SOT waives the membership fee for the first specialty section or component group you join. If you have questions or are interested in getting involved, please reach out to your graduate student or postdoctoral representatives below!

Erin Huber (Postdoctoral Rep)
hubererin0@gmail.com
Jessica Rodriguez (Graduate Student Rep)
jr1617@rutgers.edu

IVAMSS Related Research in 2024 & 2025



Sadekar N, Behrsing HP, Hansen T, Patel V, Paulo H, Rae A, Ritter D, Schwarz K, Api AM. **A proof-of-concept for safety evaluation of inhalation exposure to known respiratory irritants using *in vitro* and *in silico* methods**. *Toxics*. 2025; 13(1):35. https://doi.org/10.3390/toxics13010035

Raabe HA, Costin GE, Allen DG, Lowit A, Corvaro M, O'Dell L, Breeden-Alemi J, Page K, Perron M, Flint Silva T, Westerink W, Baker E, Sullivan K. **Human relevance of *in vivo* and *in vitro* skin irritation tests for hazard classification of pesticides.** Cutan Ocul Toxicol. 2024; Aug 24:1-21. https://doi.org/10.1080/15569527.2024.2387596

Wellnitz, J., Jain, S., Hochuli, J.E. *et al.* **One size does not fit all: revising traditional paradigms for assessing accuracy of QSAR models used for virtual screening**. *J Cheminform* 17, 7 (2025). https://doi.org/10.1186/s13321-025-00948-y

Kanďárová, H., Pôbiš, P., 2024. **The "Big Three" in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?**. *Frontiers in Toxicology*, 5. https://doi.org/10.3389/ftox.2023.1337468

Mallek NM, Martin EM, Dailey LA, McCullough SD. **Liquid application dosing alters the physiology of air-liquid interface (ALI) primary human bronchial epithelial cell/lung fibroblast co-cultures and *in vitro* testing relevant endpoints**. Front Toxicol. 2024 Jan 23;5:1264331. https://doi.org/10.3389/ftox.2023.1264331

Vitucci ECM, Simmons AE, Martin EM, McCullough SD. **Epithelial MAPK signaling directs endothelial NRF2 signaling and IL-8 secretion in a tri-culture model of the alveolar-microvascular interface following diesel exhaust particulate (DEP) exposure**. *Part Fibre Toxicol*. 2024 Mar 11;21(1):15. https://doi.org/10.1186/s12989-024-00576-8

Vitucci ECM, Carberry CK, Payton A, Herring LE, Mordant AL, Kim YH, Gilmour MI, McCullough SD, Rager JE. **Wildfire-relevant woodsmoke and extracellular vesicles (EVs): Alterations in EV proteomic signatures involved in extracellular matrix degradation and tissue injury in airway organotypic models**. *Environ Res*. 2025 Jan 1;264(Pt 2):120395. https://doi.org/10.1016/j.envres.2024.120395

Haber LT, Bradley MA, Buerger AN, Behrsing H, Burla S, Clapp PW, Dotson S, Fisher C, Genco KR, Kruszewski FH, McCullough SD, Page KE, Patel V, Pechacek N, Roper C, Sharma M, Jarabek AM. **New approach methodologies (NAMs) for the *in vitro* assessment of cleaning products for respiratory irritation: workshop repor**t. *Frontiers in Toxicology*, 2024 Oct 8;6:1431790. https://doi.org/10.3389/ftox.2024.1431790

Sharma M, Huber E, Arnesdotter E, Behrsing HP, Bettmann A, Brandwein D, Constant S, Date R, Deshpande A, Fabian E, Gupta A, Gutierrez R, Gutleb AC, Hargrove MM, Hollings M, Hutter V, Jarabek AM, Kaluzhny Y, Landsiedel R, Milchak L, Moyer RA, Murray JR, Page K, Patel M, Pearson SN, Petersen EJ, Reinke E, Roldan N, Roper C, Scaglione JB, Settivari RS, Stucki AO, Verstraelen S, Wallace JL, McCullough S, Clippinger AJ. **Minimum information for reporting on the TEER (trans-epithelial/endothelial electrical resistance) assay (MIRTA)**. Arch Toxicol. 2025 Jan;99(1):57-66. https://doi.org/10.1007/s00204-024-03879-z

Debad S, Allen D, Bandele O, Bishop C, Blaylock M, Brown P, Bunger MK, Co JY, Crosby L, Daniel AB, Ferguson SS, Ford K, Gamboa da Costa G, Gilchrist KH, Grogg MW, Gwinn M, Hartung T, Hogan SP, Jeong YE, Kass GE, Kenyon E, Kleinstreuer NC, Kujala V, Lundquist P, Matheson J, McCullough SD, Melton-Celsa A, Musser S, Oh I, Oyetade OB, Patil SU, Petersen EJ, Sadrieh N, Sayes CM, Scruggs BS, Tan YM, Thelin B, Nelson MT, Tarazona JV, Wambaugh JF, Yang JY, Yu C, Fitzpatrick S. **Trust your gut: Establishing confidence in gastrointestinal models - An overview of the state of the science and contexts of use**. *ALTEX*. 2024; 41(3):402-424. https://doi.org/10.14573/altex.2403261

IVAMSS Related Research in 2024 & 2025 cont.



Reinke EN, Reynolds J, Gilmour N, Reynolds G, Strickland J, Germolec D, Allen DJ, Gavin Maxwell, Kleinstreuer NC. **The skin allergy risk assessment-integrated chemical environment (SARA-ICE) defined approach to derive points of departure for skin sensitization.** *Current Research in Toxicology*. 2025; 8: 1-10. https://doi.org/10.1016/j.crtox.2024.100205.

Cable S, Baltazar MT, Bunglawala F, Carmichael PL, Contreas L, Dent MP, Houghton J, Kukic P, Malcomber S, Nicol B, Przybylak KR, Punt A, Reynolds G, Reynolds J, Scott S, Tang D, Middleton AM. **Advancing systemic toxicity risk assessment: Evaluation of a NAM-based toolbox approach.** *Toxicological Sciences*. 2025; 204 (1):79–95, https://doi.org/10.1093/toxsci/kfae159

de Ávila RI, Müller I, Barlow H, Middleton AM, Theiventhran M, Basili D, Bowden AM, Saib O, Engi P, Pietrenko T, Wallace J, Boda B, Constant S, Behrsing HP, Patel V and Baltazar MT. **Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety.** Front. Toxicol. 2025; 7. https://doi.org/10.3389/ftox.2025.1426132

Marimoutou, M, Patel V, Kim, JH, Schaible N, Alvarez J, Hughes J, Obermok M, Rodríguez CI, Kallarakal T, Suki B, et al. **The Fibrotic Phenotype of Human Precision-Cut Lung Slices Is Maintained after Cryopreservation.** *Toxics*. 2024; 12(637). https://doi.org/10.3390/toxics12090637

Paul Friedman K, Thomas RS, Wambaugh JF, Harrill JA, Judson RS, Shafer TJ, Williams AJ, Jia-Ying Joey Lee, Loo LH, Gagné M, Long AS, Barton-Maclaren TS, Whelan M, Bouhifd M, Rasenberg M, Simanainen U, Sobanski T. **Integration of New Approach Methods for the Assessment of Data Poor Chemicals.** *Toxicological Sciences*. 2025. https://doi.org/10.1093/toxsci/kfaf019

Ruparel N, Islas-Robles A, Hilberer A, Cantrell K, Madrid M, Ryan C, Gerberick GF, Persaud R. **Deriving a point of departure for assessing the skin sensitization risk of wearable device constituents with in vitro methods.** *Food and Chemical Toxicology*. 2024; 189(114725). https://doi.org/10.1016/j.fct.2024.114725

Cairns J, Leonard E, Khan K, Parks C, Maglennon G, Zhang B, Lazic SE, Ewart L, David R. **Optimal experimental design for efficient toxicity testing in microphysiological systems: A bone marrow application.** *Frontiers in Pharmacology*. 2023 Mar 31;14:1142581. https://doi.org/10.3389/fphar.2023.1142581

We'd love to feature your research! Reach out to us via ToXchange or our LinkedIn page!

2025 Annual Meeting

The SOT Annual Meeting will be held in **Orlando, FL March 16-20th.** Below please find a curated list of talks, posters, workshops, and activities that may be of interest to IVAMSS members. For the full meeting program, click **here**!

IVAMSS Related Activities:

Program Legend:

- Continuing Education
- Symposium/Platform Session
- Workshop/Roundtable Session
- Poster Session
- Student/Postdoc Interest
- Informational Session

IVAMSS Reception:

The IVAMSS Reception will be held on March 19th, 2025, from 6:00-7:30PM EDT in Regency Ballroom U at the Hyatt Regency.

Sunday, March 16th:

- **7:00 - 7:45am EDT**
  - **SR02: Navigating Data Management and Sharing in Computational and Predictive Toxicology**
- **8:15am – 12:00pm EDT**
  - **AM03: Dosimetry for Inhaled Substances: Advancing *In Silico* Modeling and Quantitative *In Vitro* Workflows**
  - **AM04: Key Considerations of NAM Development for Global Regulatory Harmonization**
- **1:15 – 5:00pm EDT**
  - **PM12: Utilizing New Approach Methodologies (NAMs) for Regulatory Assessment of Developmental Neurotoxicity: Progress and Prospects**
- **7:30 – 9:00pm EDT**
  - **Student/Postdoctoral Scholar Mixer**

2025 Annual Meeting: IVAMSS Related Activities

Monday, March 17th:

- **9:15am – 12:00pm EDT**
  - **When *In Vitro* Applied Dose ≠ Actual Dose: Overcoming Challenges for Next-Generation Risk Assessment for Difficult-to-Test Substances**
- **12:00 – 1:30pm EDT**
  - ***In Vitro* Toxicology Lecture and Luncheon for Students: Leveraging *In Vitro* Methods to Advance Consumer Product Safety**
- **12:10 – 1:30pm EDT**
  - **Accelerating Acceptance of New Approach Methodologies for Respiratory Toxicology Through Standardization Efforts**
  - **Recent Advances in Exposure Predictions: Model Refinement and Accessibility**
- **1:45 – 4:15pm EDT**
  - **New Approach Methods: *In Vitro* I**
  - **New Approach Methods: Computational**
- **1:45 – 4:30pm EDT**
  - **Qualifying NAMs for Developmental and Reproductive Toxicity: Advancements and Pitfalls**
- **5:00 – 6:00pm EDT**
  - **Joint Mentoring Event: MDCPSS and IVAMSS**

Tuesday, March 18th:

- **7:30 – 9:00 am EDT**
  - **SOT Mentoring Breakfast – Registration is required, space is limited**
- **8:00 – 10:45am EDT**
  - **Integrating New Approach Methodologies to Inform Sustainable Chemical Decisions**
- **11:00am – 12:20pm EDT**
  - **Bridging the Gap and Paving the Way for Future Leaders in Toxicology**
- **11:00am – 12:30pm EDT**
  - **Assessing the Metabolic Competence of *In Vitro* Models and Their Applicability in Regulatory Toxicology**
- **12:00 – 1:15pm EDT**
  - **Postdoctoral Assembly Luncheon**

2025 Annual Meeting: IVAMSS Related Activities

Tuesday, March 18th cont.:

- **1:00 – 2:30pm EDT**
  - **Applying Fit-for-Purpose Study Design to Build Confidence in NAM Use**
- **1:45 – 4:15pm EDT**
  - **Nanotoxicology: *In Vitro***
- **4:30 - 6:00pm EDT**
  - **Time After Time: Evaluating Chronic Toxicity Using NAMs to Inform Longer-Term Chemical Hazard on a Quick Timeline**
  - **Advancements in Microphysiological Systems for Toxicity Assessment: Bridging the Gap Between *In Vitro* and *In Vivo* Models**

Wednesday, March 19th:

- **8:00 – 10:45am EDT**
  - **Next-Generation *In Vitro* Neurotoxicology: Modeling Cognition-in-a-Dish**
- **9:15 – 11:45am EDT**
  - **Liver: *In Vitro***
  - **New Approach Methods: *In Vitro* II**
  - **Stem Cell Biology and Toxicology**
- **11:00 – 12:20pm EDT**
  - **Skin Deep: Navigating the Evolution and Application of Dermal Absorption Modeling in Modern Risk Assessment of Cosmetics and Personal Care Products**
- **1:30 – 4:15pm EDT**
  - **Science and Practice of Characterizing Population Variability for Regulatory Decision-Making**
- **6:00 – 7:30 EDT**
  - **IVAMSS Reception**

Thursday, March 20th:

- **8:30 – 11:15am EDT**
  - **Unlocking the Power of Read-Across for Safety Assessment: Current Practices and Approaches**

IVAMSS Related Websites

Applied *In Vitro* Toxicology	https://home.liebertpub.com/publications/applied-in-vitro-toxicology/626
Alternatives Research and Development Foundation	https://www.ardf-online.org
Alternatives to Animal Experimentation (ALTEX)	https://www.altex.org/index.php/altex
Alternatives to Laboratory Animals (ATLA)	https://frame.org.uk/what-we-do/atla-journal/
AFSA Collaboration	https://www.afsacollaboration.org/
Center for Alternatives to Animal Testing (CAAT)	https://caat.jhsph.edu
European Centre for Validation of Alternative Methods (ECVAM)	https://ec.europa.eu/jrc/en/eurl/ecvam
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)	https://ntp.niehs.nih.gov/whatwestudy/niceatm/iccvam/index.html
Japanese Center for Validation of Alternative Methods (JaCVAM)	https://www.jacvam.jp/en/index.html
NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)	https://ntp.niehs.nih.gov/whatwestudy/niceatm/index.html
Toxicology *In Vitro*	https://www.sciencedirect.com/journal/toxicology-in-vitro
Tracking System for Alternative Methods Towards Regulatory Acceptance (TSAR)	https://tsar.jrc.ec.europa.eu
Centre for Documentation and Evaluation of Alternative Methods to Animal Experiments (ZEBET)	https://www.bfr.bund.de/en/department_experimental_toxicology_and_zebet-53864.html

Thanks to our 2024-2025 Officers!

Top, from left to right: **Samantha C. Faber** (President)**, Kristie M. Sullivan** (Past President)
Middle, from left to right: **Deniz Emul** (Treasurer), **Emily Reinke** (Vice President-Elect), **Shaun McCullough** (Vice President), **Maureen Bunger** (Secretary)
Bottom, from left to right: **Erin A. Huber** (Postdoctoral Rep.), **Melissa M. Martin** (Councilor), **Anthony Bahinski** (Councilor), **Jessica R. Rodriguez** (Graduate Student Rep.)

Questions? Feedback? Want to get involved? Feel free to reach out!
IVAMSS Website IVAMSS LinkedIn